1. Volume 82, Issue 11, Pages 1223-1230 (December 2012)
Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia 
William T. Abraham, Johannes Hensen, Peter A. Gross, Daniel G. Bichet, Richard C. Josiassen, DeoDatta S. Chafekar, Cesare Orlandi 
Kidney International 
Volume 82, Issue 11, Pages (December 2012)
DOI: /ki
Copyright © 2012 International Society of Nephrology Terms and Conditions

2. Figure 1
Subject disposition. *In the placebo group, two subjects died during the treatment period and two subjects died during the 30-day follow-up period.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

3. Figure 2
Symptoms of hyponatremia in total randomized intent-to-treat (ITT) population at baseline.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

4. Figure 3
Mean central serum sodium concentration over time (intent-to-treat population (ITT), observed value). Error bars represent s.e. EOT, end of treatment (overall summary value of all end-of-treatment values, regardless of when actual end of treatment occurred); f/u 7, follow-up on day 7. *P<0.05 vs. placebo for mean change from baseline.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

5. Figure 4
Normalized daily average area under the curve (AUC) of serum sodium concentration (days 0–3 and days 0–30). *P<0.05 by ANCOVA. ANCOVA, analysis of covariance; LSM, least-squared mean.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

6. Figure 5 Time to normalization of serum sodium concentration.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions